TOPIRAMATE | A215561 | LUPIN LTD
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Supernus Pharmaceuticals, Inc. v. Lupin Limited et al 10 patentsANDA 215561topiramate extended-release | D. Del. | 2021-09-10 | Terminated 2023-11-13 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$23.21
per ea
Lowest NADAC/Unit
$3.83
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70748027806TOPIRAMATE ER 200 MG CAPSULE | $23.21 | EA | Generic | — | 2026-06-17 |
| 70748027706TOPIRAMATE ER 100 MG CAPSULE | $10.76 | EA | Generic | — | 2026-06-17 |
| 70748027606TOPIRAMATE ER 50 MG CAPSULE | $6.27 | EA | Generic | — | 2026-06-17 |
| 70748027506TOPIRAMATE ER 25 MG CAPSULE | $3.83 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.